Minerva Neurosciences (NASDAQ:NERV) Stock Passes Below 50-Day Moving Average – Time to Sell?

Minerva Neurosciences, Inc. (NASDAQ:NERV) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.33 and traded as low as $2.13. Minerva Neurosciences shares last traded at $2.14, with a volume of 16,335 shares trading hands.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NERV. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th. StockNews.com assumed coverage on Minerva Neurosciences in a report on Friday. They issued a “sell” rating for the company.

Minerva Neurosciences Trading Up 0.9 %

The firm has a market cap of $15.10 million, a P/E ratio of -4.91 and a beta of 0.11. The business’s 50-day moving average is $2.32 and its two-hundred day moving average is $2.74.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.